D-SPARK: D-Serine for Modifying Parkinson's Disease Progression
Overview
Mermaid diagram (expand to render)
D-SPARK is a Phase 2 clinical trial evaluating D-serine, an endogenous N-methyl-D-aspartate receptor (NMDAR) co-agonist, as a potential disease-modifying treatment for Parkinson's disease["@dserine2023"]. The trial is sponsored by Haukeland University Hospital and aims to determine whether D-serine can slow or modify the progression of PD through modulation of glutamatergic neurotransmission["@haukeland"].
The rationale for D-serine in PD stems from growing evidence that NMDAR hypofunction contributes to dopaminergic neuronal loss, while proper NMDAR signaling is essential for synaptic plasticity and neuronal survival in the substantia nigra["@nmdar2022"]. By enhancing NMDAR activation through D-serine supplementation, the trial seeks to protect remaining dopaminergic neurons and potentially improve motor and non-motor symptoms["@damino2022"].
Evaluate the safety and tolerability of D-serine in Parkinson's disease patients
Assess disease modification potential through motor and non-motor symptom progression
Determine optimal dosing regimen for neuroprotective effects
Inclusion Criteria
Diagnosis of Parkinson's disease (UK Brain Bank criteria)
Age 40-80 years
Disease duration 1-10 years
Stable dopaminergic medication for at least 4 weeks
MMSE score ≥ 24
Exclusion Criteria
Significant cognitive impairment (MMSE < 24)
Psychiatric disorders requiring current treatment
History of seizures or epilepsy
Significant renal or hepatic impairment
Current use of NMDAR antagonists
Mechanism of Action
D-Serine as NMDAR Co-Agonist
D-serine is the primary endogenous co-agonist of the N-methyl-D-aspartate receptor, acting at the glycine modulatory site (GlyB)[@dserine]. Unlike glycine, D-serine has higher brain bioavailability and is synthesized predominantly in astrocytes, making it the primary regulator of NMDAR function in the central nervous system[@astrocytic2020].
The NMDAR requires two distinct co-agonists for activation:
Glutamate (the primary neurotransmitter)
D-serine or glycine (the co-agonist)
Under physiological conditions, D-serine occupancy at the GlyB site is approximately 60-80%, leaving room for pharmacologic enhancement[@glycine].
Neuroprotective Mechanisms
D-serine-mediated NMDAR activation exerts neuroprotection through several interconnected pathways:
Synaptic Plasticity Enhancement
NMDAR activation promotes long-term potentiation (LTP) in dopaminergic neurons
Enhances dendritic spine density in the substantia nigra
Improves synaptic connectivity and function
Anti-Apoptotic Signaling
Activates PI3K/Akt survival pathways
Inhibits caspase-3 activation
Prevents mitochondrial dysfunction
Anti-Inflammatory Effects
Modulates microglial activation states
Reduces pro-inflammatory cytokine release
Decreases neuroinflammation-mediated neuronal loss
Calcium Homeostasis
Regulates Ca2+ influx through NMDAR
Promotes appropriate calcium signaling for neuronal survival
Prevents excitotoxic damage while maintaining physiological function
Relevance to Parkinson's Disease Pathology
In PD, multiple factors contribute to NMDAR dysfunction:
Dopaminergic denervation reduces D-serine release from substantia nigra neurons
Glial dysfunction impairs D-serine synthesis and recycling
Oxidative stress alters NMDAR subunit composition and function
These changes result in NMDAR hypofunction, which may accelerate dopaminergic neuron death through impaired plasticity and reduced trophic support[@dopaminenmdar2019]. D-serine supplementation aims to correct this hypofunction and restore protective NMDAR signaling.
Preclinical Evidence
Animal Model Studies
Preclinical studies in various PD animal models have demonstrated:
MPTP-induced parkinsonism: D-serine administration protected dopaminergic neurons from MPTP toxicity
6-OHDA model: D-serine improved behavioral outcomes and reduced lesion volume
α-synuclein transgenic models: D-serine attenuated neurodegeneration and motor deficits
Mechanistic Studies
D-serine levels are reduced in the substantia nigra of PD patients[@dserinea]
NMDAR subunits show altered expression in PD brains[@nmdar2020]
GlyB site agonists show promise in neuroprotective paradigms[@glycine2021]
Study Design
Randomization and Blinding
Patients will be randomized 1:1 to receive either:
D-serine (dose TBD)
Matching placebo
Double-blind design ensures neither patients nor investigators know the allocation.